Metagenomi Therapeutics, Inc. logo

Metagenomi Therapeutics, Inc. (MGX) Q4 2024 Annual Earnings

MGX·Reported March 17, 2025·Before market open

Metagenomi Therapeutics, Inc. reported Q4 2024 revenue of $9.6M, beat analyst consensus of $9.2M by $382.7K. Diluted EPS came in at $-0.63, missed the $-0.62 consensus by $0.01.

Revenue
$9.6Mbeat by $382.7K
Consensus: $9.2M
Diluted EPS
$-0.63missed by $0.01
Consensus: $-0.62
SEC

SEC Filings

Earnings release8-K not filed yet
Annual report10-K · 0000950170-25-040217

Financial Snapshot

Trailing eight quarters through Q4 2024

View all metrics

Revenue

View metric

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q4 2024 Earnings FAQ

Common questions about Metagenomi Therapeutics, Inc. 's Q4 2024 earnings report.

Metagenomi Therapeutics, Inc. (MGX) reported Q4 2024 earnings on March 17, 2025 before market open.

Metagenomi Therapeutics, Inc. reported revenue of $9.6M and diluted EPS of $-0.63 for Q4 2024.

Revenue beat the consensus estimate of $9.2M by $382.7K. EPS missed the consensus estimate of $-0.62 by $0.01.

You can read the 10-K periodic report (0000950170-25-040217) directly on SEC EDGAR. The filing index links above go to sec.gov.